Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

HIV Infection

Free Subscription 29.09.2025 4 AIDS 4 Clin Infect Dis 3 HIV Med 3 J Immunol 13 J Infect Dis 1 J Med Virol 1 J Virol 1 MMWR Morb Mortal Wkly Rep 1 Pediatrics 1 PLoS Comput Biol 10 PLoS One 1 PLoS Pathog 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. VAN DEUZEN CM, Rijnders BJA, Bax HI, Rokx C, et al
   Cerebral toxoplasmosis in the twenty-first century: long-term clinical outcomes in a retrospective cohort study in the Netherlands.
   AIDS. 2025 Sep 23. doi: 10.1097/QAD.0000000000004356.
   PubMed         Abstract available
   
   
2. MILIC J, Calza S, Lazzarini L, Cocchi M, et al
   Prevalence and risk factors of cognitive frailty in people with HIV.
   AIDS. 2025 Sep 19. doi: 10.1097/QAD.0000000000004352.
   PubMed         Abstract available
   
   
3. DIETERICH DT, Brunet L, Hsu RK, Mounzer K, et al
   Tenofovir interruption among people with HIV and HBV: HBV monitoring and risk of HBV reactivation and hepatitis flare.
   AIDS. 2025 Sep 19. doi: 10.1097/QAD.0000000000004353.
   PubMed         Abstract available
   
   
4. STOLTZ TT, Jensen AMR, Roed AKH, Frikke-Schmidt R, et al
   Plasma levels of lipoprotein(a) in persons with HIV compared to the general population.
   AIDS. 2025 Sep 19. doi: 10.1097/QAD.0000000000004349.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

5. BOLDUC P, Barakat LA, Sherman EM, Day PG, et al
   Promoting Human Immunodeficiency Virus Syndemic Care in Health Professions Education: Linking Workforce Demands to the Aspirations of a Rising Generation.
   Clin Infect Dis. 2025 Sep 23:ciaf347. doi: 10.1093.
   PubMed         Abstract available
   
   
6. LLIBRE JM, Ripamonti D, Geretti AM, Martin-Iguacel R, et al
   Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.
   Clin Infect Dis. 2025 Sep 23:ciaf471. doi: 10.1093.
   PubMed         Abstract available
   
   
7. LEOCADIO C, Garcia E, Lash M, Berardi J, et al
   Clinical Outcomes of Mpox Disease in Patients Treated with Tecovirimat.
   Clin Infect Dis. 2025 Sep 19:ciaf520. doi: 10.1093.
   PubMed         Abstract available
   
   
8. MANN SC, Lykins D, Coyle RP, Witt MD, et al
   In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort.
   Clin Infect Dis. 2025 Sep 17:ciaf509. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   HIV Med

9. SAVINELLI S, Heeney A, Tinago W, Garcia Leon AA, et al
   People living with HIV on modern antiretrovirals do not display a pro-atherogenic lipid profile and have similar body composition compared to healthy controls.
   HIV Med. 2025 Sep 24. doi: 10.1111/hiv.70118.
   PubMed         Abstract available
   
   
10. AVALLONE F, Engler K, Hickson F, Cox J, et al
    Sexual dysfunction care needs of gay, bisexual, and other men who have sex with men living with HIV in Montreal, Canada.
    HIV Med. 2025 Sep 22. doi: 10.1111/hiv.70115.
    PubMed         Abstract available
    
    
11. FARINA F, Datta A, Morin SN, Saeed S, et al
    Intersections of vitamin D deficiency, HIV and chronic liver diseases.
    HIV Med. 2025 Sep 20. doi: 10.1111/hiv.70117.
    PubMed         Abstract available
    
    

    
    J Immunol

12. SUBIA NT, Awamura TK, Dean LS, Loftis K, et al
    Dysregulation of complement components associated with inflammation and coagulation in virally suppressed people living with HIV.
    J Immunol. 2025 Sep 15:vkaf227. doi: 10.1093.
    PubMed         Abstract available
    
    
13. PREMEAUX TA, Yeung ST, Johnson SD, Moar P, et al
    Altered distribution of tissue galectins correlates with mucosal dysregulation in SIV infection.
    J Immunol. 2025 Sep 15:vkaf200. doi: 10.1093.
    PubMed         Abstract available
    
    
14. MATHEWS J, Van Itallie E, Li Y, Wiehe K, et al
    Computing the inducibility of broadly neutralizing antibodies under a context-dependent model of affinity maturation: applications to sequential vaccine design.
    J Immunol. 2025 Sep 13:vkaf234. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Infect Dis

15. PAN C, Xu H, Huang M, He J, et al
    Mycobacterium tuberculosis PE_PGRS62 protein inhibits type I IFN responses to promote HIV-2 replication by directly interacting with IRF3.
    J Infect Dis. 2025 Sep 17:jiaf484. doi: 10.1093.
    PubMed         Abstract available
    
    
16. BARTEE M, Yessick L, Maloney J, Tomlinson H, et al
    Diagonal Investments in Health Systems: PEPFAR's Approach to Sustaining the HIV Response and Enhancing Global Health Security.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
17. VERANI AR, Samo Gudo E, Chilengi R, Bratton S, et al
    PEPFAR Investments in National Public Health Institutes: HIV Control Through Strong Systems.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
18. CHIKWANDA P, Stevens T, Mwangi C, Phiri C, et al
    Leveraging Laboratory Information Management Systems to Support HIV and Other Infectious Diseases Testing in PEPFAR-Supported Countries.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
19. ALEMNJI G, Sangthong A, Espy N, Bartee M, et al
    PEPFAR Laboratory Implementation Strategy as a Component of PEPFAR's 5-Year Strategy.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
20. OKOYE M, Okoi C, Espy N, Mba N, et al
    Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
21. BAPTISTE SL, Barr E, Reid MJA, Campbell DM, et al
    Unpacking the Role, Nature, and Need to Sustain Robust Community Responses in Global Systems.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
22. MATTOCKS L, Celestin N, Francois K, Joseph P, et al
    PEPFAR Investments in Country Data Systems Support HIV Treatment Continuity: An Example From Haiti.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
23. GOMES DJ, Bancroft EA, Lawal I, Zender N, et al
    Advancing Infection Prevention and Control in the United States PEPFAR Programs.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
24. ALEMNJI G, Zeh C, Bhairavabhotla R, Wattleworth M, et al
    Implementation of All-inclusive Global Purchasing Agreements for Viral Load and Infant Diagnosis in PEPFAR-Supported Countries.
    J Infect Dis. 2025;232.
    PubMed         Abstract available
    
    
25. SMITH C, Curtis K, Bonham A, Boyer S, et al
    Maternal Inflammation Likely Drives Impaired Immune Responses to Respiratory Syncytial Virus in HIV-Exposed Uninfected Infants.
    J Infect Dis. 2025 Sep 24:jiaf493. doi: 10.1093.
    PubMed         Abstract available
    
    
26. KOGILWAIMATH S, Utay NS
    "Fostemsavir: More Than Meets the Eye".
    J Infect Dis. 2025 Sep 24:jiaf462. doi: 10.1093.
    PubMed        
    
    
27. BENLARBI M, Richard J, Clemente T, Bourassa C, et al
    Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV.
    J Infect Dis. 2025 Sep 24:jiaf461. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Med Virol

28. HE J, Tian T, Tuo X, Yu W, et al
    Determinants of Changes in HPV Vaccination Willingness Among Men Who Have Sex With Men: An Observational Cohort Study.
    J Med Virol. 2025;97:e70611.
    PubMed         Abstract available
    
    

    
    J Virol

29. SHAO Q, Wang Y, Hildreth JEK, Liu B, et al
    Correction for Shao et al., "Polyubiquitination of APOBEC3G Is Essential for Its Degradation by HIV-1 Vif".
    J Virol. 2025 Sep 23:e0136825. doi: 10.1128/jvi.01368.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

30. PATEL RR, Hoover KW, Lale A, Cabrales J, et al
    Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:541-549.
    PubMed         Abstract available
    
    

    
    Pediatrics

31. MARTIN EG, Avila Acosta M, Pepin DA, Huang YA, et al
    HIV Preexposure Prophylaxis Prescriptions, Consent Laws, and Uptake Barriers Among Adolescents.
    Pediatrics. 2025 Sep 19:e2024069808. doi: 10.1542/peds.2024-069808.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

32. SAMBATURU N, Lapp Z, Tria FDK, Romero-Severson E, et al
    wavess: An R package for simulation of adaptive within-host virus sequence evolution.
    PLoS Comput Biol. 2025;21:e1013437.
    PubMed         Abstract available
    
    

    
    PLoS One

33. CHAKULYA M, Muchaili L, Hatwiko H, Mutalange M, et al
    Anaemia and associated factors in people living with HIV on ART in Southern Province of Zambia.
    PLoS One. 2025;20:e0331643.
    PubMed         Abstract available
    
    
34. JATILENI V, Nicol E
    A protocol for an assessment of the health information system in Khomas region, Namibia.
    PLoS One. 2025;20:e0306939.
    PubMed         Abstract available
    
    
35. TUNNICLIFFE L, Muzambi R, Bartlett JW, Howe LD, et al
    Infection and telomere length: A systematic review.
    PLoS One. 2025;20:e0333107.
    PubMed         Abstract available
    
    
36. SEQUERA-ARQUELLADAS S, Vivancos MJ, Vinuesa D, Collado A, et al
    Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial.
    PLoS One. 2025;20:e0323167.
    PubMed         Abstract available
    
    
37. DUBE TN, Mboniswa F, Qwana SE, Charalambous S, et al
    "If we lose it, we are worried": Individual and provider level perceptions towards weight change among people living with HIV who undergo TB screening in routine health care settings in Gauteng Province, South Africa.
    PLoS One. 2025;20:e0331904.
    PubMed         Abstract available
    
    
38. BASHORUN AO, Kotei L, Jallow AF, Jawla O, et al
    Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol.
    PLoS One. 2025;20:e0332842.
    PubMed         Abstract available
    
    
39. 
    Editorial Note: Incidence and predictors of HIV related opportunistic infections after initiation of highly active antiretroviral therapy at Ayder Referral Hospital, Mekelle, Ethiopia: A retrospective single centered cohort study.
    PLoS One. 2025;20:e0332767.
    PubMed        
    
    
40. HASSAN SA, Sheikh N, Basualdo G, Daniel N, et al
    Harambee! 2.0: Community resources and resilience factors to leverage for improving HIV testing behaviors among African immigrant communities in Seattle, Washington.
    PLoS One. 2025;20:e0331915.
    PubMed         Abstract available
    
    
41. DEMISSIE AA, Rensburg EJV
    Healthcare providers' perspectives of barriers and facilitators to highly active antiretroviral therapy adherence among HIV-positive women in Southern Ethiopia: A qualitative study.
    PLoS One. 2025;20:e0312980.
    PubMed         Abstract available
    
    
42. WEN J, Ma X, Zhou X, Kissell RC, et al
    Molecular basis for the activation of the bitter taste receptor TAS2R14 by Ritonavir.
    PLoS One. 2025;20:e0332704.
    PubMed         Abstract available
    
    

    
    PLoS Pathog

43. CHOSHI P, Pedretti S, Chimbetete T, Gangula R, et al
    The association of class II HLA alleles with tuberculosis-associated immune reconstitution inflammatory syndrome.
    PLoS Pathog. 2025;21:e1013497.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

44. ALENCAR GF, Mohamed AO, Burnett MG, Jean SS, et al
    Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2419888122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.